Does impaired vitamin B6 status alter kynurenine pathway handling?

Vitamin B6, specifically its active coenzyme form pyridoxal 5'-phosphate (PLP), serves as a critical regulatory node in the kynurenine pathway of tryptophan metabolism. This metabolic cascade is highly sensitive to nutritional status, which is especially relevant for maintaining metabolic and neurological health in older adults.

Biochemical mechanisms of pathway disruption

• Enzymatic cofactor dependency: PLP binds covalently to active-site lysine residues on kynureninase and kynurenine aminotransferases (KATs). Impaired B6 status depletes active holoenzymes, directly reducing their catalytic capacity.
• Differential enzyme sensitivity: Kynureninase is highly sensitive to PLP depletion and undergoes a rapid, pronounced loss of activity compared to KAT.
• Impaired NAD+ synthesis: The resulting kynureninase block prevents the conversion of kynurenine and 3-hydroxykynurenine (3-HK) into anthranilic acid and 3-hydroxyanthranilic acid (3-HAA), restricting downstream pathway flux toward NAD+ synthesis.

Metabolite shifts and biomarker profiles

• Xanthurenic acid shunt: Because the primary pathway is blocked, accumulating 3-HK is preferentially shunted toward alternative metabolic branches, leading to the excessive formation of xanthurenic acid (XA).
• Functional biomarkers: This pathway diversion significantly raises systemic levels of kynurenine, 3-HK, and XA. Consequently, shifted substrate-product ratios—specifically 3-HK/XA and HK/XA—serve as highly sensitive functional biomarkers of intracellular vitamin B6 deficiency.

Bottom line

• Impaired vitamin B6 status directly downregulates the PLP-dependent enzymes kynureninase and KAT, shifting tryptophan metabolism away from NAD+ synthesis and driving the accumulation of downstream metabolites like 3-hydroxykynurenine and xanthurenic acid.